Boothbay Fund Management’s Definium Therapeutics DFTX Stock Holding History

Boothbay Fund Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,096	Closed	-$266K	–	2486
2026 Q1	$266K	Buy	+14,096	New	+$239K	﹤0.01%	1659
2025 Q4	–	Sell	-67,984	Closed	-$802K	–	2213
2025 Q3	$802K	Buy	67,984 +50,000	+278%	+$466K	0.01%	925
2025 Q2	$117K	Hold	17,984	–	–	﹤0.01%	1300
2025 Q1	$105K	Hold	17,984	–	–	﹤0.01%	1225
2024 Q4	$125K	Buy	17,984 +210	+1%	+$1.45K	﹤0.01%	1256
2024 Q3	$101K	Sell	17,774 -28,447	-62%	-$198K	﹤0.01%	1457
2024 Q2	$333K	Sell	46,221 -38,403	-45%	-$336K	0.01%	1127
2024 Q1	$795K	Sell	84,624 -62,036	-42%	-$354K	0.02%	831
2023 Q4	$537K	Buy	+146,660	New	+$442K	0.01%	967
2022 Q2	–	Sell	-736	Closed	-$12K	–	2509
2022 Q1	$12K	Hold	736	–	–	﹤0.01%	2233
2021 Q4	$15K	Buy	+736	New	+$23.5K	﹤0.01%	1801

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Boothbay Fund Management's DFTX Position: Q2 2026 in Review

Boothbay Fund Management sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 14,096 shares — an estimated $266K sold.

Boothbay Fund Management first reported a position in DFTX in Q4 2021 and held it in 11 quarters. The position peaked at $802K in Q3 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Boothbay Fund Management reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 14,096 Definium Therapeutics shares in Q2 2026, an estimated $266K.
Boothbay Fund Management first reported a position in Definium Therapeutics in Q4 2021 and held it in 11 quarters.
Boothbay Fund Management's Definium Therapeutics position peaked at $802K in Q3 2025.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.